Company news
Bubs Australia Ltd. (ASX:BUB) news
Bubs Australia Ltd. news releases on 6ix. Latest, Sep 6, 2026: Bubs Secures Permanent US FDA Approval for Infant Formula
Press releases & updates
Bubs Secures Permanent US FDA Approval for Infant Formula
September 6, 2026
FY26 Results Presentation
August 26, 2026
FY26 Trading Update
May 28, 2026
Bubs Australia - Half Year Results Presentation
February 26, 2026
Bubs Australia - Half Year Results Commentary
February 26, 2026
Bubs Australia - Half Year Report and Appendix 4D
February 26, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2026
AGM Presentation
November 20, 2025
ALPHA GROUP LEGAL DISPUTE UPDATE
November 5, 2025
New Chair and MD Appointments
September 14, 2025
FY25 Appendix 4E Preliminary Final Report
August 29, 2025
CEO Appointment Joe Coote
July 28, 2025
BUBS SUBMITS CLINICAL TRIAL DATA TO US FDA
June 15, 2025
Alpha Group Legal Dispute Update
April 29, 2025
Bubs Q1 FY25 Quarterly Activity and Cashflow Statement
October 30, 2024
Bubs Clinical Trial Update - 400th Patient Enrolment
September 16, 2024
Bubs - FY24 Appendix 4E Preliminary Final Report
August 27, 2024
Bubs Q4 FY24 Quarterly Activity and Cashflow Statement
July 28, 2024
Bubs Trading Update
June 13, 2024
Bubs Q3 FY24 Quarterly Activity and Cashflow Statement
April 29, 2024
Bubs US Growth Continues at Pace
March 17, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
Bubs Q2 FY24 Quarterly Activity and Cashflow Statement
January 30, 2024
BUBS USA Growth Accelerates
December 10, 2023
Completion of $14M Placement and Launches SPP
November 23, 2023
Capital Raising Investor Presentation
November 23, 2023
Trading Halt
November 21, 2023
Bubs Q1 FY24 Quarterly Activity and Cashflow Statement
October 23, 2023
Bubs Announces US-Based Infant Formula Clinical Trial
September 6, 2023
Bubs FY23 Results
August 31, 2023
Bubs Appendix 4E - Preliminary Final Report
August 31, 2023
Bubs CEO Appointment
August 28, 2023
Bubs Q4 FY23 Quarterly Activity and Cashflow Statement
July 30, 2023
Strategic Review - Presentation
July 5, 2023
Strategic Review
July 5, 2023
Alpha Group Legal Dispute
July 3, 2023
Bubs China Update
June 30, 2023
USA Update
June 20, 2023
Trading Update
June 2, 2023
Bubs Australia Limited - CEO Termination
May 10, 2023
FY23 Q3 - Activity Report and Appendix 4C Cashflow Statement
April 27, 2023
Half Year Results and Appendix 4D
February 27, 2023
Non - Cash Impairment
February 27, 2023
Pause in Trading
February 26, 2023
FY23 Q2 - Activity Report and Appendix 4C Cashflow Statement
January 30, 2023
FY23 Q1 - Activity Report and Appendix 4C Cashflow Statement
October 30, 2022
Bubs Lodges Letter of Intent with FDA
October 2, 2022
SAMR Registration Pathway Bubs China Label Infant Formula
September 28, 2022
Appendix 4E
August 29, 2022
Bubs Australia : Completion of Retail Entitlement Offer - Amended
July 29, 2022